Cargando…

Reprogramming systemic and local immune function to empower immunotherapy against glioblastoma

The limited benefits of immunotherapy against glioblastoma (GBM) is closely related to the paucity of T cells in brain tumor bed. Both systemic and local immunosuppression contribute to the deficiency of tumor-infiltrating T cells. However, the current studies focus heavily on the local immunosuppre...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhou, Songlei, Huang, Yukun, Chen, Yu, Liu, Yipu, Xie, Laozhi, You, Yang, Tong, Shiqiang, Xu, Jianpei, Jiang, Gan, Song, Qingxiang, Mei, Ni, Ma, Fenfen, Gao, Xiaoling, Chen, Hongzhuan, Chen, Jun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9880004/
https://www.ncbi.nlm.nih.gov/pubmed/36702831
http://dx.doi.org/10.1038/s41467-023-35957-8
_version_ 1784878816726876160
author Zhou, Songlei
Huang, Yukun
Chen, Yu
Liu, Yipu
Xie, Laozhi
You, Yang
Tong, Shiqiang
Xu, Jianpei
Jiang, Gan
Song, Qingxiang
Mei, Ni
Ma, Fenfen
Gao, Xiaoling
Chen, Hongzhuan
Chen, Jun
author_facet Zhou, Songlei
Huang, Yukun
Chen, Yu
Liu, Yipu
Xie, Laozhi
You, Yang
Tong, Shiqiang
Xu, Jianpei
Jiang, Gan
Song, Qingxiang
Mei, Ni
Ma, Fenfen
Gao, Xiaoling
Chen, Hongzhuan
Chen, Jun
author_sort Zhou, Songlei
collection PubMed
description The limited benefits of immunotherapy against glioblastoma (GBM) is closely related to the paucity of T cells in brain tumor bed. Both systemic and local immunosuppression contribute to the deficiency of tumor-infiltrating T cells. However, the current studies focus heavily on the local immunosuppressive tumor microenvironment but not on the co-existence of systemic immunosuppression. Here, we develop a nanostructure named Nano-reshaper to co-encapsulate lymphopenia alleviating agent cannabidiol and lymphocyte recruiting cytokine LIGHT. The results show that Nano-reshaper increases the number of systemic T cells and improves local T-cell recruitment condition, thus greatly increasing T-cell infiltration. When combined with immune checkpoint inhibitor, this therapeutic modality achieves 83.3% long-term survivors without recurrence in GBM models in male mice. Collectively, this work unveils that simultaneous reprogramming of systemic and local immune function is critical for T-cell based immunotherapy and provides a clinically translatable option for combating brain tumors.
format Online
Article
Text
id pubmed-9880004
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Nature Publishing Group UK
record_format MEDLINE/PubMed
spelling pubmed-98800042023-01-28 Reprogramming systemic and local immune function to empower immunotherapy against glioblastoma Zhou, Songlei Huang, Yukun Chen, Yu Liu, Yipu Xie, Laozhi You, Yang Tong, Shiqiang Xu, Jianpei Jiang, Gan Song, Qingxiang Mei, Ni Ma, Fenfen Gao, Xiaoling Chen, Hongzhuan Chen, Jun Nat Commun Article The limited benefits of immunotherapy against glioblastoma (GBM) is closely related to the paucity of T cells in brain tumor bed. Both systemic and local immunosuppression contribute to the deficiency of tumor-infiltrating T cells. However, the current studies focus heavily on the local immunosuppressive tumor microenvironment but not on the co-existence of systemic immunosuppression. Here, we develop a nanostructure named Nano-reshaper to co-encapsulate lymphopenia alleviating agent cannabidiol and lymphocyte recruiting cytokine LIGHT. The results show that Nano-reshaper increases the number of systemic T cells and improves local T-cell recruitment condition, thus greatly increasing T-cell infiltration. When combined with immune checkpoint inhibitor, this therapeutic modality achieves 83.3% long-term survivors without recurrence in GBM models in male mice. Collectively, this work unveils that simultaneous reprogramming of systemic and local immune function is critical for T-cell based immunotherapy and provides a clinically translatable option for combating brain tumors. Nature Publishing Group UK 2023-01-26 /pmc/articles/PMC9880004/ /pubmed/36702831 http://dx.doi.org/10.1038/s41467-023-35957-8 Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Article
Zhou, Songlei
Huang, Yukun
Chen, Yu
Liu, Yipu
Xie, Laozhi
You, Yang
Tong, Shiqiang
Xu, Jianpei
Jiang, Gan
Song, Qingxiang
Mei, Ni
Ma, Fenfen
Gao, Xiaoling
Chen, Hongzhuan
Chen, Jun
Reprogramming systemic and local immune function to empower immunotherapy against glioblastoma
title Reprogramming systemic and local immune function to empower immunotherapy against glioblastoma
title_full Reprogramming systemic and local immune function to empower immunotherapy against glioblastoma
title_fullStr Reprogramming systemic and local immune function to empower immunotherapy against glioblastoma
title_full_unstemmed Reprogramming systemic and local immune function to empower immunotherapy against glioblastoma
title_short Reprogramming systemic and local immune function to empower immunotherapy against glioblastoma
title_sort reprogramming systemic and local immune function to empower immunotherapy against glioblastoma
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9880004/
https://www.ncbi.nlm.nih.gov/pubmed/36702831
http://dx.doi.org/10.1038/s41467-023-35957-8
work_keys_str_mv AT zhousonglei reprogrammingsystemicandlocalimmunefunctiontoempowerimmunotherapyagainstglioblastoma
AT huangyukun reprogrammingsystemicandlocalimmunefunctiontoempowerimmunotherapyagainstglioblastoma
AT chenyu reprogrammingsystemicandlocalimmunefunctiontoempowerimmunotherapyagainstglioblastoma
AT liuyipu reprogrammingsystemicandlocalimmunefunctiontoempowerimmunotherapyagainstglioblastoma
AT xielaozhi reprogrammingsystemicandlocalimmunefunctiontoempowerimmunotherapyagainstglioblastoma
AT youyang reprogrammingsystemicandlocalimmunefunctiontoempowerimmunotherapyagainstglioblastoma
AT tongshiqiang reprogrammingsystemicandlocalimmunefunctiontoempowerimmunotherapyagainstglioblastoma
AT xujianpei reprogrammingsystemicandlocalimmunefunctiontoempowerimmunotherapyagainstglioblastoma
AT jianggan reprogrammingsystemicandlocalimmunefunctiontoempowerimmunotherapyagainstglioblastoma
AT songqingxiang reprogrammingsystemicandlocalimmunefunctiontoempowerimmunotherapyagainstglioblastoma
AT meini reprogrammingsystemicandlocalimmunefunctiontoempowerimmunotherapyagainstglioblastoma
AT mafenfen reprogrammingsystemicandlocalimmunefunctiontoempowerimmunotherapyagainstglioblastoma
AT gaoxiaoling reprogrammingsystemicandlocalimmunefunctiontoempowerimmunotherapyagainstglioblastoma
AT chenhongzhuan reprogrammingsystemicandlocalimmunefunctiontoempowerimmunotherapyagainstglioblastoma
AT chenjun reprogrammingsystemicandlocalimmunefunctiontoempowerimmunotherapyagainstglioblastoma